Skip to content
10-Q

Quarterly Report

Theravance Biopharma, Inc. TBPH

0001558370-25-007398

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 50M sh
Stockholders Equity Q1 2025 · Mar 31, 2025 $165.98M
Stockholders Equity Q1 2025 · Dec 31, 2024 $175.55M
Stockholders Equity Q1 2025 · Mar 31, 2024 $204.87M
Stockholders Equity Q1 2025 · Dec 31, 2023 $213M
Current Liabilities Q1 2025 · Mar 31, 2025 $31.5M
Current Liabilities Q1 2025 · Dec 31, 2024 $32.09M
Current Assets Q1 2025 · Mar 31, 2025 $150.26M
Current Assets Q1 2025 · Dec 31, 2024 $161.07M
Total Assets Q1 2025 · Mar 31, 2025 $343.58M
Total Assets Q1 2025 · Dec 31, 2024 $354.16M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $37.8M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $53.84M
Shares Diluted Q1 2025 · Mar 31, 2024 48.28M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $445K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$1.02M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.24
Eps Basic Q1 2025 · Mar 31, 2024 −$0.24
Sga Expense Q1 2025 · Mar 31, 2024 $16.74M
Rd Expense Q1 2025 · Mar 31, 2024 $8.97M
Net Income Q1 2025 · Mar 31, 2024 −$11.66M
Operating Income Q1 2025 · Mar 31, 2024 −$11.21M
Revenue Q1 2025 · Mar 31, 2024 $14.5M